regdanvimab
Trade name: Regkirona
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Aug 18, 2022 (NCT05982704)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Spike glycoproteinINHIBITOR
Spike glycoprotein inhibitor
- SARS-CoV-2Immunity, passive
immunity, passive - sars-cov-2
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650462 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05982704 | Phase 4 | Aug 18, 2022 | Government of Russia |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Russia | Government | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1